🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. Budigalimab, Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT, ABBV-382, Placebo for ABBV-382 Solution for Infusion

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial

  2. Budigalimab, Telisotuzumab adizutecan, Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Advanced or Metastatic Non-Squamous NSCLC

    phase 2 small molecule active

    1 trial

  3. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  4. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial

  5. CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coat

    Fondazione Telethon ETS

    bladder carcinoma of urothelial and non-urothelial histology

    phase 2 small molecule active

    1 trial

  6. CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  7. CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  8. CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 small molecule active

    1 trial

  9. CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé, Capecitabine Accord 150 mg film-coated tablets, Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Capecitabin "Zentiva", filmovertrukne tabletter, Capecitabina Zentiva 500 mg compresse rivestite con film., Capecitabine Zentiva 150 mg filmdragerade tabletter, Capecitabin "Zentiva", filmovertrukne tabletter, CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé,

    GlaxoSmithKline

    MMRp/ MSS colon cancer

    phase 2 small molecule active

    1 trial

  10. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial

  11. CARBOPLATIN , ETOPOSIDE , ENZALUTAMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, MK-7684A, DOCETAXEL , Belzutifan, Lenvatinib, Lenvatinib, PREDNISONE , ABIRATERONE , DEXAMETHASONE , Olaparib

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  12. CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.

    phase 2 small molecule active

    1 trial

  13. CARBOPLATIN, BEVACIZUMAB, MK-4830, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

    Merck Sharp and Dohme

    Primary peritoneal cancer/Fallopian tube cancer

    phase 2 small molecule active

    1 trial

  14. CARBOPLATIN, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, ETOPOSIDE, CISPLATIN, Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil Accord 250 mg capsules, Inflectra 100 mg powder for concentrate for solution for infusion, TAGRISSO 80 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for sol

    AstraZeneca AB

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. CART infusion

    Hospital Authority, Hong Kong

    B-cell Lymphoma Refractory

    phase 2 other active

    1 trial

  16. CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  17. CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, FLUOROURACIL

    Takeda

    Solid Neoplasm

    phase 2 small molecule active

    1 trial

  18. CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, LIBTAYO 350 mg concentrate for solution for infusion.

    Talion

    non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  19. CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE

    The George Institute

    Extrahepatic cholangiocarcinoma (eCCA)

    phase 2 small molecule active

    1 trial

  20. CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. CISPLATINE VIATRIS 25 mg/25 ml, solution à diluer pour perfusion, Tecentriq 1 200 mg concentrate for solution for infusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  22. CISPLATINO SANDOZ, LIBTAYO 350 mg concentrate for solution for infusion.

    Fondazione Telethon ETS

    locally advanced cervical carcinoma

    phase 2 small molecule active

    1 trial

  23. CRIZOTINIB, CRIZOTINIB, XALKORI 200 mg hard capsules, CRIZOTINIB, CRIZOTINIB, CRIZOTINIB, XALKORI 250 mg hard capsules, Torisel 30 mg concentrate and solvent for solution for infusion

    Disc Medicine

    Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)

    phase 2 small molecule active

    1 trial

  24. CYCLOPHOSPHAMIDE MONOHYDRATE, VINORELBINE, Tecentriq 840 mg concentrate for solution for infusion

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources